# Neurorevix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurorevix

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Latest round: Angel (Sep 28, 2026)
- Investors on record: 2

## About

Based in Beijing, China, and founded in 2025, Beijing Tianfukang Medical Technology Co., Ltd., trading as Neurorevix, is an innovative medical device enterprise focused on brain-computer interface (BCI) and neuromodulation technologies.
In September 2026, Neurorevix raised an Angel funding led by HSG, with participation from YuanMing Capital.
Neurorevix, focusing on BCI and neuromodulation, has built a technology platform centered on "BCI combined with precise closed-loop nerve bundle modulation." The Company has strategically developed flexible electrodes, dedicated BCI chips, and adaptive closed-loop algorithms. It is committed to advancing this platform technology—driven by clinical needs—to develop and commercialize a series of global "first-in-class" products.
The company’s revenue is generated by providing flexible electrodes, dedicated BCI chips, and adaptive closed-loop algorithms. 
Moving forward, Neurorevix will continue to refine its foundational technology platforms—focusing on areas such as advanced flexible array neural electrodes, dedicated BCI chips, and algorithms for neural signal decoding and closed-loop modulation—while constantly exploring cutting-edge frontiers like distributed BCIs and visual function restoration, driven by the genuine needs of patients.

## Funding rounds

- Angel, Sep 28, 2026 — YuanMing Capital, HSG

## Investors

- YuanMing Capital (https://capitalatlas.ai/funds/yuanming-capital) — Angel
- HSG (https://capitalatlas.ai/funds/hsg) — Angel